Earnings visibility is difficult due to the multi-faceted nature of Sagent's generic drug business, however, CEO Jeffrey Yordon says he anticipates a strong first quarter after seeing sales rise 20% in Q4. He expects Sagent to launch between 12 and 16 new products this year after launching a dozen last year. Yordon also says the company's new Chinese plant is already FDA-approved and manufacturing products, and he has high expectations for Sagent's research center in Chengdu China.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Jim Cramer: I've Liked Six Flags Entertainment Stock as an Income Producer

Jim Cramer: I've Liked Six Flags Entertainment Stock as an Income Producer

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Jim Cramer on Autonomous Driving Prowess of Texas Instruments

Jim Cramer on Autonomous Driving Prowess of Texas Instruments

Video: Jim Cramer on Caterpillar, Boeing, Twitter and Texas Instruments

Video: Jim Cramer on Caterpillar, Boeing, Twitter and Texas Instruments

Jim Cramer on Earnings: All Stories Aren't Equal

Jim Cramer on Earnings: All Stories Aren't Equal